Equillium, Inc. (EQ) Form 8-K — May 13, 2026
Equillium, Inc. reported financial results for the first quarter ended March 31, 2026, with a net loss of $5.3 million, or $(0.06) per share, compared to a net loss of $8.7 million, or $(0.24) per share, in the same period of 2025. The decrease in net loss was primarily due to lower R&D and G&A expenses. The company appointed Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy.
Key figures
- Eps
- -0.06
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -5.311
- Total Debt
- 0
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 63,083
- Cash Position
- 61,322
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 96,279,216
- G&A expenses
- 2,619
- R&D expenses
- 2,991
- Cash and cash equivalents (Q1 2026)
- 61,322
- Cash and cash equivalents (Q4 2025)
- 30,277
Price after filing
1 day: +12.1%7 days: -10.8%30 days: +21.6%
Close on the filing date to close N calendar days later (from $2.31). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.